Benefits
Visceral fat reduction (10-week trial)
At 200 mg/day, Oligonol showed significant decreases in body weight, abdominal circumference, and visceral fat volume — roughly 15% visceral fat reduction, 6% subcutaneous fat reduction, and ~3 cm waist reduction, with insulin resistance improving and adiponectin rising. Small sample limits definitive conclusions, but effect sizes were substantial.
Cortisol and inflammatory cytokine reduction
Clinical evidence confirms anti-inflammatory effects through cortisol, IL-1β, and IL-6 reduction in healthy young men. Supports the broader cardiometabolic positioning beyond pure body composition effects.
Peripheral circulation improvement
A pilot study using infrared thermography showed 50 mg Oligonol® improved peripheral blood circulation via nitric oxide production. Demonstrates a rapid microcirculatory effect with single-dose evidence — relevant for those with cold extremities or sluggish circulation.
Skin health and anti-aging effects
Multiple trials report skin-health applications including wrinkle and brown spot reduction. The anti-aging cosmeceutical positioning is supported by polyphenol antioxidant and anti-inflammatory effects on dermal tissue.
Exercise fatigue and endurance
Multiple trials report exercise fatigue reduction and endurance improvements. Likely combines the antioxidant, anti-inflammatory, and circulation-enhancing mechanisms — relevant for active adults and recreational athletes.
Post-meal blood glucose and lipid support
Trials show improvements in post-meal glycemic and lipid responses, supporting the cardiometabolic adjunct positioning beyond visceral fat alone.
Adiponectin elevation (mechanistic significance)
Adiponectin is a key insulin-sensitizing adipokine; circulating levels typically decrease with visceral adiposity and metabolic syndrome. Oligonol elevating adiponectin is mechanistically significant — addresses fundamental adipose dysfunction rather than only weight or body composition. Same mechanism direction as PPAR-γ agonists (thiazolidinediones) but via natural polyphenol pathways.
Mechanism of action
Low-molecular-weight oligomeric procyanidin bioavailability
The proprietary depolymerization process converts high-MW lychee polyphenols (poorly absorbed in typical lychee extracts) into low-MW oligomers that are much better absorbed. The distinguishing pharmacokinetic advantage of Oligonol vs generic lychee polyphenol products.
Adiponectin elevation
Adiponectin is a key insulin-sensitizing adipokine that typically decreases with visceral adiposity. Oligonol elevates adiponectin — addresses fundamental adipose dysfunction rather than only weight/body composition.
Insulin sensitivity improvement
Insulin sensitivity improved alongside the body composition changes — a multi-target metabolic effect.
Cortisol reduction (HPA axis modulation)
Cortisol reduction via HPA axis modulation. A stress-reduction mechanism complementing the metabolic effects.
NO production via PKC-dependent NADPH oxidase activation
Nitric oxide production via a PKC-dependent NADPH oxidase activation pathway. Vasodilation mechanism for the peripheral circulation effect.
Visceral adipocyte ROS reduction
Visceral adipocyte reactive oxygen species reduction contributes to adipose tissue normalization and adiponectin restoration.
Anti-inflammatory cytokine modulation (IL-1β, IL-6)
IL-1β and IL-6 reduction — anti-inflammatory cytokine modulation supporting both metabolic and stress-related effects.
Clinical trials
(J Funct Foods 1(4):341-348).
Clinical population described in trial publication.
(J Funct Foods 1(4):341-348). Pivotal visceral fat 10-week clinical trial (n=18) at 200 mg/day. Significant body weight, abdominal circumference, and visceral fat volume decreases (15% visceral fat reduction; 6% subcutaneous fat reduction; ~3 cm waist reduction). Insulin resistance improved with adiponectin elevation. Hokkaido Information University, Sapporo Bio-S, and Amino Up Chemical Company collaboration.
(Nutr Res Pract 4(3):203-207).
Clinical population described in trial publication.
(Nutr Res Pract 4(3):203-207). First human trial confirming anti-inflammatory role through cortisol, IL-1β, and IL-6 inhibition in healthy young men.
(Natural Medicine Journal 6(7)).
Clinical population described in trial publication.
(Natural Medicine Journal 6(7)). Peripheral circulation pilot using infrared thermography. 50 mg Oligonol® improved blood circulation via NO production.